Armand Glassman to Follow-Up Studies
This is a "connection" page, showing publications Armand Glassman has written about Follow-Up Studies.
Connection Strength
0.034
-
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005 Jun 15; 105(12):4573-5.
Score: 0.010
-
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6.
Score: 0.010
-
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95.
Score: 0.009
-
Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993 Jul; 4(4):285-94.
Score: 0.004